Nuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-Market

Core Viewpoint - Nuwellis, Inc. has announced a securities purchase agreement for a private placement of shares and warrants, aiming to raise approximately $5 million to support its operations in precision cardiorenal care [1][3]. Group 1: Private Placement Details - The company will sell 994,537 shares of common stock at an effective offering price of $3.09 per share, along with warrants to purchase 1,989,074 additional shares [1]. - The warrants will have an exercise price of $2.84 per share, exercisable immediately upon issuance, and will expire five years after a resale registration statement becomes effective [1]. Group 2: Warrant Inducement Agreement - Nuwellis has entered into a warrant inducement agreement with an investor to immediately exercise certain existing warrants at a reduced exercise price of $3.09, allowing the purchase of 623,585 shares [2]. - In exchange for the immediate exercise, the company will issue new unregistered warrants for an additional 1,247,170 shares at the same exercise price of $2.84, also expiring five years after the effective registration statement [2]. Group 3: Financial Proceeds and Closing - The gross proceeds from both the private placement and the warrant inducement are expected to be around $5 million before deducting fees and expenses, with the closing anticipated on or about January 30, 2026 [3]. - Ladenburg Thalmann & Co. Inc. is acting as the sole placement agent for these transactions [3]. Group 4: Company Overview - Nuwellis, Inc. is focused on advancing precision fluid management technologies for cardiorenal conditions, developing solutions for patient care through monitoring and therapy [6]. - The company is headquartered in Minneapolis, Minnesota, and aims to support clinical decision-making across various care settings [6][7]. Group 5: Product Information - The Aquadex SmartFlow system is a key product that provides therapy for patients with hypervolemia, indicated for both temporary and extended use in specific patient populations [9].